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Abstract 
The use of carbamazepine has been reported to be an effective treatment for 
severe depression. We have already shown that the antidepressant-like 
effects of tricyclic antidepressants in the rat forced swim test (FST) are 
blocked by chronic treatment with adrenocorticotropic hormone (ACTH). In 
the present study, we examined the effect of the chronic administration of 
carbamazepine on the FST and the wet-dog shakes induced by 
(±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A 
receptor agonist, in ACTH-treated rats. Chronic administration of 
carbamazepine did not affect the duration of immobility in saline-treated and 
ACTH-treated rats. The reduction of immobility, induced by chronic 
administration of imipramine, was blocked by treatment with ACTH. When 
carbamazepine was administered concurrently with imipramine, we 
observed a significant decrease in immobility in rats treated with ACTH. 
Chronic ACTH treatment increased the number of the wet-dog shakes 
induced by DOI. This effect of ACTH was significantly increased by the 
coadministration of carbamazepine and imipramine. These results suggest 
that the use of carbamazepine together with tricyclic antidepressants had the 
effect of reducing immobility time in the FST in a tricyclic 
antidepressant-treatment-resistant depressive model induced by chronic 
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ACTH treatment.  
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Introduction 
 
We previously reported that the reduction in the duration of immobility in 
the forced swim test (FST) caused by the chronic administration of 
imipramine was inhibited by chronic treatment with adrenocorticotropic 
hormone (ACTH) (Kitamura et al., 2002a). Furthermore, chronic 
coadministration of lithium, an agent which potentiates the actions of 
antidepressants in patients with depression, including those with 
treatment-resistant depression (de Montigny et el., 1981), significantly 
decreased the duration of immobility, even when given concurrently with 
ACTH (Kitamura et al., 2002a). Namely, we reported that ACTH-treated rats 
served a valuable animal model of tricyclic antidepressant-resistant 
depressive conditions. 
The Serotonin (5-HT) receptor subtypes, particularly the 5-HT2A receptor, 
have been postulated to play an important role in the pathogenesis of 
depression (Arango et al., 1990; Arora and Meltzer, 1989; Biegon et al., 
1987; Mann et al., 1986; Pandey et al., 2002). However, 
psychoendocrinological studies have focused on the regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis in patients with depression 
(Carroll et al., 1976). Information on the mechanism whereby steroid 
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hormones regulate 5-HT function will impact on our understanding of 
hypercortisolism, a condition typical of affective disorders and 
treatment-resistant depression (Christie et al., 1986). We previously reported 
chronic administration of corticosterone or ACTH increased the number of 
wet-dog shakes induced by 
(±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A 
receptor agonist (Takao et al., 1997, Kitamura et al., 2002b; Kawakami et al., 
2005). The DOI-induced wet-dog shakes is mediated by 5-HT2A receptor 
function. This animal model of activation of the HPA axis may shed light on 
the mechanism governing the 5-HT2A receptor’s up-regulation, a condition 
associated with the pathophysiology of depression. Namely, a model of the 
hyperfunction of 5-HT2A receptors induced by chronic treatment with ACTH 
may be useful for examining the mechanism of action of antidepressant 
drugs for tricyclic antidepressant-treatment-resistant depression.  
Carbamazepine is an antiepileptic and mood-stabilizing drug. It has also 
been shown to be effective in the treatment of several forms of affective 
disorders, such as treatment-resistant depression (Calabrese and Delucchi, 
1989; Kramlinger and Post, 1989). Although previous reports have evaluated 
the effect of carbamazepine in naive animals, few attempts have been made 
to examine its effects in a model of abnormal activation of the HPA axis. 
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The purpose of the present study was to examine the effect of 
carbamazepine and coadministration of imipramine and carbamazepine on 
the duration of immobility in the FST and 5-HT2A receptor-mediated 
behavioral responses induced by DOI in ACTH-treated rats. 
 
Materials and Methods 
 
Animals 
Male Wistar rats (Charles River, Japan) weighing 180-230 g, were utilized 
in this study. The rats were kept under a constant light-dark cycle (lights on, 
07.00 - 19.00 h), with access to standard laboratory food and tap water in an 
air-conditioned room (23 ± 1 °C with approximately 60% humidity). All 
experiments were conducted according to the guidelines for Animal 
Experimentation at Okayama University Medical School. Every effort was 
made to minimize the number of animals used and their suffering. 
 
Drugs 
 
The following drugs were used in the study: carbamazepine (Sigma-Aldrich, 
St. Louis, MO, USA), imipramine hydrochloride (Wako Pure Chemical., 
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Osaka, Japan), DOI ((±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
(Sigma-Aldrich, St. Louis, MO, USA) and ACTH-(1-24)-Zinc 
(Cortrosyn-Z : Daiichi Seiyaku Co., Tokyo, Japan). Carbamazepine was 
suspended in a 0.5% methylcellulose solution. Imipramine and DOI were 
dissolved in saline. The drugs were freshly prepared and injected in a 
volume of 2 ml/kg body weight. Rats were administered drugs once daily 
(09.00 to 10.00 h). Control rats received an equivalent volume of the 0.5% 
methylcellulose solution or saline for the same treatment period. Six to 8 
animals were used for each experimental group. 
 
Behavioral studies 
 
Measurement of immobility 
 
To measure immobility, rats were individually placed in plastic cylinders 
(height 37 cm, diameter 15.5 cm) containing 20 cm of water at 25 °C, as 
described by Porsolt et al. (1978). Two swim sessions were conducted in the 
initial 13 min pre-test; a 6 min test followed 24 h later. The total period of 
immobility during the 6 min testing period was recorded using the TARGET 
series/7M analysis program (Neuroscience Inc., Tokyo, Japan). 
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Measurement of DOI-induced wet-dog shakes 
 
Rats were placed in individual clear polycarbonate home cages (35×30×17 
cm) and treated with DOI (1 mg/kg, s.c.). The DOI-induced wet-dog shakes 
were counted over the first 30 min commencing immediately following the 
injection. Wet-dog shakes were identified as a paroxysmal shudder of the 
head, neck, and trunk. The observers were blinded to the drug 
administrations. 
 
Experiment 1: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on the duration of immobility in saline-treated rats 
 
We chronically administered imipramine (10 mg/kg, i.p.), carbamazepine 
(3-30 mg/kg, i.p.), or both imipramine (10 mg/kg, i.p.) and carbamazepine 
(30 mg/kg, i.p.) to normal rats once daily for 15 days. The final treatment 
with imipramine or carbamazepine on day 15 was given 30 min before the 
observation. 
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Experiment 2: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on the duration of immobility in ACTH-treated rats 
 
We chronically administered imipramine (10 mg/kg, i.p.), carbamazepine 
(30 mg/kg, i.p.), or both imipramine (10 mg/kg, i.p.) and carbamazepine (30 
mg/kg, i.p.) to ACTH (100 µg/day, s.c.)-treated rats. These treatment 
combinations were given once daily for 14 days. On the 15th day, doses of 
imipramine and carbamazepine were given without ACTH. The immobility 
was observed 30 min after the administration of imipramine and 
carbamazepine. 
 
Experiment 3: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on DOI-induced wet-dog shakes in saline-treated rats 
 
We chronically administered imipramine (10 mg/kg, i.p.), carbamazepine 
(3-30 mg/kg, i.p.), or both imipramine (10 mg/kg, i.p.) and carbamazepine 
(30 mg/kg, i.p.) to normal rats once daily for 14 days. The number of DOI (1 
mg/kg, s.c.)-induced wet-dog shakes was recorded 1 day after the final 
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administration of imipramine and carbamazepine. 
 
Experiment 4: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on DOI-induced wet-dog shakes in ACTH-treated rats 
 
We chronically administered imipramine (10 mg/kg, i.p.), carbamazepine 
(30 mg/kg, i.p.), or both imipramine (10 mg/kg, i.p.) and carbamazepine (30 
mg/kg, i.p.) to ACTH (100 µg/day, s.c.)-treated rats. These treatment 
combinations were given once daily for 14 days. The number of DOI (1 
mg/kg, s.c.)-induced wet-dog shakes was recorded 1 day after the final 
administration of ACTH, imipramine, and carbamazepine. 
 
Statistics 
 
Values are expressed as the mean ± S.E.M. Data were analyzed with a 
one-way analysis of variance (ANOVA); the group means were 
compared using  Dunnett’s test or Tukey’s test for multiple comparisons. 
Probability values of less than 0.05 were considered to show a significant 
difference. 
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Results 
 
Experiment 1: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on the duration of immobility in saline-treated rats 
 
The administration of carbamazepine (3 – 30 mg/kg, i.p.) for a period of 15 
days had no effect on the duration of immobility in the FST [F(3,20)=0.75, 
P=0.53] (Fig. 1A). The administration of imipramine (10 mg/kg, i.p.) for 15 
days significantly decreased the duration of immobility in the FST 
[F(2,15)=5.42, P<0.05] (Fig 1B). The effect of imipramine on the duration 
of immobility did not change with the coadministration of carbamazepine 
(Fig. 1B). 
 
Experiment 2: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on the duration of immobility in ACTH-treated rats 
 
The administration of carbamazepine (30 mg/kg, i.p.) for 15 days had no 
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effect on the duration of immobility in the FST in ACTH-treated rats 
[F(2,15)=1.41, P=0.28] (Fig 2A). The administration of imipramine (10 
mg/kg, i.p.) decreased the duration of immobility (Fig. 1B), an effect 
blocked by 14 days of treatment with ACTH (Fig. 2B). Coadministration of 
imipramine (10 mg/kg, i.p.) and carbamazepine (30 mg/kg, i.p.) significantly 
decreased the duration of immobility [F(3,28)=4.76, P<0.05] (Fig. 2B). 
 
Experiment 3: Effects of chronic administration of imipramine or 
carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on DOI-induced wet-dog shakes in saline-treated rats 
 
The administration of carbamazepine (3 – 30 mg/kg, i.p.) for 14 days had no 
effect on the number of DOI-induced wet-dog shakes [F(3,20)=2.14, 
P=0.13] (Fig. 3A). The administration of imipramine (10 mg/kg, i.p.) for 14 
days significantly decreased the number of DOI-induced wet-dog shakes 
[F(2,15)=4.09, P<0.05] (Fig 3B). The effect of imipramine on the number of 
DOI-induced wet-dog shakes did not change with the coadministration of 
carbamazepine (Fig. 3B). 
 
Experiment 4: Effects of chronic administration of imipramine or 
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carbamazepine, and chronic coadministration of imipramine and 
carbamazepine on DOI-induced wet-dog shakes in ACTH-treated rats 
 
The number of DOI-induced wet-dog shakes was increased in ACTH-treated 
rats compared to saline-treated rats [F(2,15)=7.82, P<0.05] (Fig. 4A). This 
increase was not affected by the administration of carbamazepine (30 mg/kg, 
i.p.) for 14 days (Fig. 4A). However, the number of DOI-induced wet-dog 
shakes was increased by the coadministration of imipramine (10 mg/kg, i.p.) 
and carbamazepine (30 mg/kg, i.p.) compared to that in ACTH-treated rats 
[F(3,28)=27.42, P<0.05] (Fig. 4B). 
 
Discussion 
 
It is the results of the present study suggest that the chronic 
coadministration of imipramine and carbamazepine and carbamazepine 
caused a significant decrease in immobility in the FST in rats treated with 
ACTH for 14 days. We previously reported that chronic treatment with 
ACTH inhibited the immobility-decreasing effects of imipramine (Kitamura 
et al., 2002a). The current findings confirmed the results of repeated 
imipramine administration in ACTH-treated rats. Clinically, the use of 
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lithium has been shown to be effective in the treatment of several forms of 
affective disorders, such as treatment-resistant depression. Using lithium 
together with tricyclic antidepressants may be a promising way to improve 
the efficacy of the treatment of resistant depression. It was reported that the 
inhibition of the immobility-decreasing effect of imipramine was reversed 
by coadministration of lithium in ACTH-treated rats in the FST (Kitamura et 
al., 2002a). Furthermore, we reported that repeated electroconvulsive stimuli 
decreased the duration of immobility in the FST in chronic ACTH-treated 
rats (Li et al., 2006). Electroconvulsive stimuli therapy is considered to be 
the most effective biological treatment for depression, especially severe 
intractable depression (Fink et al., 1990). These findings suggest that the 
chronic coadministration of lithium and imipramine, and repeated 
electroconvulsive stimuli produce an antidepressant-like effect in an animal 
model of the abnormal activation of the HPA axis induced by ACTH. The 
results of the present study suggest that the chronic coadministration of 
imipramine and carbamazepine caused a significant decrease in immobility 
in the FST in rats treated with ACTH for 14 days. The combination of 
carbamazepine and imipramine (a tricyclic antidepressant) may be an 
effective treatment for tricyclic antidepressant-resistant depression the same 
as the augmentation strategy for treatment-resistant depression using lithium. 
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The chronic administration of ACTH, a treatment that up-regulates 
activation of the HPA axis, increases the density of 5-HT2A receptors in the 
forebrain neocortex and the number of wet-dog shakes induced by DOI, a 
5-HT2A receptor agonist (Kuroda et al., 1992; Kitamura et al., 2002b, 2007). 
We recognized that the expression levels of 5-HT2A receptor mRNA increase 
with the chronic administration of ACTH (Kitamura et al., in press). 
Furthermore, the enhancing effect on DOI-induced wet-dog shakes is 
blocked by the coadministration of lithium and imipramine, but not by 
imipramine alone (Kitamura et al., 2002b). Thus, it is proposed that the 
5-HT2A receptor’s hyperfunction is related to the animal model for tricyclic 
antidepressant-treatment-resistant depressive conditions induced by chronic 
ACTH treatment. Furthermore, inhibition of the 5-HT2A receptor’s function 
may contribute to the therapeutic treatment of tricyclic 
antidepressant-resistant depression. In this study, chronic administration of 
carbamazepine did not affect the number of DOI-induced wet-dog shakes of 
naive rats. The increasing effect of ACTH was not influenced by the chronic 
administration of carbamazepine. The chronic coadministration of 
imipramine and carbamazepine significantly increased the number of 
DOI-induced wet-dog shakes in rats treated with ACTH. A previous report 
suggested that the chronic administration of carbamazepine increased 5-HT2 
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receptor-mediated head twitching behavior after an injection of carbidopa 
followed by 5-hydroxytryptophan. On the other hand, the chronic 
administration of carbamazepine did not alter the binding of the 5-HT2 
receptor in the rat frontal cortex (Elphick et al., 1990). The effect of 
carbamazepine on the 5-HT2 receptor’s function is conflicting. Previously, 
we reported that repeated electroconvulsive stimuli significantly increased 
the number of DOI-induced wet-dog shakes in both saline and 
ACTH-treated rats (Li et al., 2006), as in the present study. This result, 
indicating that the coadministration of imipramine and carbamazepine, and 
electroconvulsive stimuli action resulted in a disparity between the FST and 
DOI-induced wet-dog shakes, did not support the hypothesis that the 5-HT2A 
receptor’s hyperfunction is involved in the animal model for tricyclic 
antidepressant-treatment-resistant depressive conditions induced by chronic 
ACTH treatment (Kitamura et al., 2002b). Namely, it may mean that 
inhibition of the 5-HT2A receptor’s function is not a common mechanism 
behind the effect of antidepressants. It is reported that stimulation of the 
β–adrenergic receptor with isoproterenol increased cyclic adenosine 
monophosphate levels and this effect was significantly inhibited by 
carbamazepine. (Montezinho et al., 2006). The density of β–adrenergic 
receptors decreased after chronic treatment of rats with tricyclic 
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antidepressant drugs (Kellar, 1987). Therefore, further studies are needed to 
determine whether or not β–adrenergic receptors are involved in the 
antidepressant-like action of carbamazepine in ACTH-treated rats. 
 In summary, chronic administration of carbamazepine did not change 
the duration of immobility in the FST in saline-treated and ACTH-treated 
rats. Chronic coadministration of imipramine and carbamazepine decreased 
the duration of immobility in the FST in ACTH-treated rats. Furthermore, 
the chronic coadministration of imipramine and carbamazepine did not 
improve the 5-HT2A receptor’s hyperfunction induced by chronic ACTH 
treatment.  
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Legends 
 
Fig. 1. Effects of chronic administration of carbamazepine (A), or both 
imipramine and carbamazepine (B) on the duration of immobility in the FST 
in rats.  
Imipramine (IMI) and carbamazepine (CBZ) were administered to rats once 
daily for 15 days. Control (cont) rats were treated with a 0.5% 
methylcellulose solution (2 ml/kg, i.p.) or saline (2 ml/kg, i.p.) once daily for 
15 days. The immobility time was measured the day following the final 
treatment. The final administrations of imipramine and carbamazepine were 
given 30 min before the measurement. Values are expressed as the means ± 
S.E.M. for six animals. Data were analyzed by one-way ANOVA, followed 
by Dunnett’s test (A) and Tukey’s test (B). * P<0.05, significant difference 
from the control value.  
 
Fig. 2. Effects of chronic administration of carbamazepine (A), or both 
imipramine and carbamazepine (B) on the duration of immobility in the FST 
for ACTH-treated rats. ACTH (100 µg/day, s.c.), imipramine (IMI: 10 mg/kg, 
i.p.) and carbamazepine (CBZ: 30 mg/kg, i.p.) were administered to rats 
once daily for 14 days. Control (cont) rats were treated with a 0.5% 
 25
methylcellulose solution (2 ml/kg, i.p.) or saline (0.2 ml/rat, s.c. and 2 ml/kg, 
i.p.) once daily for 14 days. The immobility time was measured the day 
following the final treatment with ACTH. Imipramine and carbamazepine 
were administered 30 min before the measurement. Values are expressed as 
the means ± S.E.M. for 6-8 animals. Data were analyzed by one-way 
ANOVA, followed by Tukey’s test. ** P<0.01, significant difference from 
the control value, # P<0.05, significant difference from the ACTH treatment. 
 
Fig. 3. Effects of chronic administration of carbamazepine (A), or both 
imipramine and carbamazepine (B) on DOI-induced wet-dog shakes in rats.  
Imipramine (IMI) and carbamazepine (CBZ) were administered to rats once 
daily for 14 days. Control (cont) rats were treated with a 0.5% 
methylcellulose solution (2 ml/kg, i.p.) or saline (2 ml/kg, i.p.) once daily for 
14 days. The number of DOI-induced wet-dog shakes were counted on the 
day following the final treatment. Values are expressed as the means ± 
S.E.M. for eight animals. Data were analyzed by one-way ANOVA, 
followed by Dunnett’s test (A) and Tukey’s test (B). * P<0.05, significant 
difference from the control value.  
 
Fig. 4. Effects of chronic administration of carbamazepine (A), or both 
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imipramine and carbamazepine (B) on DOI-induced wet-dog shakes in 
ACTH-treated rats. ACTH (100 µg/day, s.c.), imipramine (IMI: 10 mg/kg, 
i.p.) and carbamazepine (CBZ: 30 mg/kg, i.p.) were administered to rats 
once daily for 14 days. Control (cont) rats were treated with a 0.5% 
methylcellulose solution (2 ml/kg, i.p.) or saline (0.2 ml/rat, s.c. and 2 ml/kg, 
i.p.) once daily for 14 days. The number of DOI-induced wet-dog shakes 
were counted the day following the final treatment. Values are expressed as 
the means ± S.E.M. for 6-8 animals. Data were analyzed by one-way 
ANOVA, followed by Tukey’s test. * P<0.05, ** P<0.01, significant 
difference from the control value, # # P<0.01, significant difference from the 
ACTH treatment.  
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